Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141934 · ClinicalTrials.gov registry record · Phase 2
A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.
A Phase 2 study of Rheumatoid Arthritis, sponsored by Sosei.
- Completed
- Registry status
- Phase 2
- Development phase
- 232
- Enrollment target
- 10
- Study locations
NCT00141934: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by Sosei.
NCT00141934 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Sosei. The registered enrollment target is 232 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141934, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Sosei.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 232 participants
- Enrollment target
- 10
- Study locations
Study Summary
AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and safety, AD 452 is being tested in a 3 month study. Patients enrolled in this study will already be taking methotrexate for their RA and they will remain on methotrexate throughout the study. An earlier clinical study in 98 subjects with RA on stable background therapy investigated the pharmacokinetics, safety and tolerability of AD 452 taken for one month. The drug was well tolerated and no significant drug related adverse events were reported.
Conditions Studied
Interventions
- DRUG AD 452
Study Locations (10)
Florida
- Clinical Research of West Florida, Inc - Clearwater
- Center for Rheumatology, Immunology and Arthritis - Fort Lauderdale
- Ocala Rheumatology Research Center - Ocala
- Sarasota Arthritis Research Center - Sarasota
- Advent Clinical Research Centers, Inc. - St. Petersburg
New Jersey
- Anderson and Collins Clinical Research, Inc. - Edison
- Station Avenue - Haddon Heights
- Atlantic Coast Research LLC - Toms River
Maryland
- Dept of Rheumatology, Columbia Medical Practice - Columbia
Pennsylvania
- Rheumatic Disease Associates - Willow Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00141934 record still lists
NCT00141934 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AD 452 is the first listed.
NCT00141934 lists 10 locations in 4 states (Florida, New Jersey, Maryland).
Frequently Asked Questions
What is clinical trial NCT00141934 about?
NCT00141934 is a clinical study titled "A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.". AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and safety, AD 452 is being tested in a 3 month study. Patients enrolled in thi...
What is the current status of trial NCT00141934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 232 participants. The study started on 2005-08.
What conditions does trial NCT00141934 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00141934?
The interventions under investigation include: AD 452 (DRUG).
Who is sponsoring clinical trial NCT00141934?
This trial is sponsored by Sosei, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141934 being conducted?
This trial has 10 study locations across Florida, Maryland, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00141934's enrollment target sits among peer trials
232 77th of 197 higher than 121 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia